NUVB250117C7500
- 0.05
- 0.000.00%
Nuvation Bio Newsroom
Nuvation Bio Up Nearly 17%, on Track for Largest Percent Increase Since March 2024 -- Data Talk
UniFirst, Getty Images, Shutterstock And Other Big Stocks Moving Higher On Tuesday
RBC Capital Maintains Nuvation Bio(NUVB.US) With Buy Rating, Raises Target Price to $10
Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Express News | Nuvation Bio Inc - Taletrectinib to Be Marketed in China by Innovent Biologics
HC Wainwright & Co. Reiterates Buy on Nuvation Bio, Maintains $7 Price Target
Buy Rating on Nuvation Bio: Promising Taletrectinib Results and Strong Valuation Support $7 Target
Institutional Investors May Overlook Nuvation Bio Inc.'s (NYSE:NUVB) Recent US$54m Market Cap Drop as Long-term Gains Remain Positive
Why Is Nuvation Bio (NUVB) the Best Biotech Penny Stock to Invest in Now?
Sector Update: Health Care Stocks Fall Premarket Monday
Nuvation Bio Announces The U.S. FDA Accepts For Priority Review Nuvation Bio's New Drug Application For Taletrectinib For The Treatment Of Advanced ROS1-Positive Non-Small Cell Lung Cancer
Express News | Nuvation Bio Inc - FDA Assigns Target Action Date of June 23, 2025
Express News | U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced Ros1-Positive Non-Small Cell Lung Cancer
Express News | Innovent Receives Approval of Dovbleron® (Taletrectinib Adipate Capsule, Ros1 Inhibitor) by China's National Medical Products Administration
Clear Street Launches Healthcare & Biotechnology Equity Research
Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference
Is Nuvation Bio (NYSE:NUVB) Using Too Much Debt?
Nuvation Bio's Q3 2024 Highlights and Future Prospects
Nuvation Bio to Present at the Jefferies London Healthcare Conference
Top 4 Health Care Stocks That May Plunge This Quarter